Institution
University of British Columbia
Education•Vancouver, British Columbia, Canada•
About: University of British Columbia is a education organization based out in Vancouver, British Columbia, Canada. It is known for research contribution in the topics: Population & Poison control. The organization has 89939 authors who have published 209679 publications receiving 9226862 citations. The organization is also known as: UBC & The University of British Columbia.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, the authors reported frequent mutations in the heterotrimeric G protein alpha-subunit, GNAQ, in blue naevi (83%), and ocular melanoma of the uvea (46%).
Abstract: BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures, and lead to constitutive activation of the mitogen-activated protein (MAP) kinase pathway. However, BRAF and NRAS mutations are absent in a number of other melanocytic neoplasms in which the equivalent oncogenic events are currently unknown. Here we report frequent somatic mutations in the heterotrimeric G protein alpha-subunit, GNAQ, in blue naevi (83%) and ocular melanoma of the uvea (46%). The mutations occur exclusively in codon 209 in the Ras-like domain and result in constitutive activation, turning GNAQ into a dominant acting oncogene. Our results demonstrate an alternative route to MAP kinase activation in melanocytic neoplasia, providing new opportunities for therapeutic intervention.
1,266 citations
••
TL;DR: It is confirmed that illusory conjunctions are frequently experienced among unattended stimuli varying in color and shape, and that they occur also with size and solidity (outlined versus filled-in shapes).
1,262 citations
••
TL;DR: In this paper, the authors propose a statisticalique du rapport de vraisemblance construite a partir de la distribution conditionnelle des observations, and donne les estimateurs du maximum de VRAISEMblance for les parametres de nuisance.
Abstract: On propose une statistique du rapport de vraisemblance construite a partir de la distribution conditionnelle des observations, etant donne les estimateurs du maximum de vraisemblance pour les parametres de nuisance
1,261 citations
••
TL;DR: Strong evidence for dust and no statistically significant evidence for tensor modes is found and various model variations and extensions are probe, including adding a synchrotron component in combination with lower frequency data, and find that these make little difference to the r constraint.
Abstract: We report the results of a joint analysis of data from BICEP2/Keck Array and Planck. BICEP2 and Keck Array have observed the same approximately 400 deg2 patch of sky centered on RA 0h, Dec. −57.5deg. The combined maps reach a depth of 57 nK deg in Stokes Q and U in a band centered at 150 GHz. Planck has observed the full sky in polarization at seven frequencies from 30 to 353 GHz, but much less deeply in any given region (1.2 μK deg in Q and U at 143 GHz). We detect 150×353 cross-correlation in B-modes at high significance. We fit the single- and cross-frequency power spectra at frequencies above 150 GHz to a lensed-ΛCDM model that includes dust and a possible contribution from inflationary gravitational waves (as parameterized by the tensor-to-scalar ratio r). We probe various model variations and extensions, including adding a synchrotron component in combination with lower frequency data, and find that these make little difference to the r constraint. Finally we present an alternative analysis which is similar to a map-based cleaning of the dust contribution, and show that this gives similar constraints. The final result is expressed as a likelihood curve for r, and yields an upper limit r0.05<0.12 at 95% confidence. Marginalizing over dust and r, lensing B-modes are detected at 7.0σ significance.
1,255 citations
••
University of Texas MD Anderson Cancer Center1, University of Washington2, Loyola University Chicago3, Mayo Clinic4, University of Miami5, University of British Columbia6, Wayne State University7, Washington University in St. Louis8, Georgetown University9, University of California, Los Angeles10, University of Alabama at Birmingham11, Memorial Sloan Kettering Cancer Center12, University of Cologne13, Seattle Genetics14, City of Hope National Medical Center15
TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).
Abstract: Purpose Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas. Patients and Methods In this multinational, open-label, phase II study, the efficacy and safety of brentuximab vedotin were evaluated in patients with relapsed or refractory Hodgkin’s lymphoma (HL) after autologous stem-cell transplantation (auto-SCT). Patients had histologically documented CD30-positive HL by central pathology review. A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks. In the absence of disease progression or prohibitive toxicity, patients received a maximum of 16 cycles. The primary end point was the overall objective response rate (ORR) determined by an independent radiology review facility. Results The ORR was 75% with complete remission (CR) in 34% of patients. The median progression-free survival time for all patients was 5.6 months, and the median duration of response for those in CR was 20.5 months. After a median observation time of more than 1.5 years, 31 patients were alive and free of documented progressive disease. The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. Conclusion The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy. J Clin Oncol 30:2183-2189. © 2012 by American Society of Clinical Oncology
1,254 citations
Authors
Showing all 90682 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gordon H. Guyatt | 231 | 1620 | 228631 |
John C. Morris | 183 | 1441 | 168413 |
Douglas Scott | 178 | 1111 | 185229 |
John R. Yates | 177 | 1036 | 129029 |
Deborah J. Cook | 173 | 907 | 148928 |
Richard A. Gibbs | 172 | 889 | 249708 |
Evan E. Eichler | 170 | 567 | 150409 |
James F. Sallis | 169 | 825 | 144836 |
Michael Snyder | 169 | 840 | 130225 |
Jiawei Han | 168 | 1233 | 143427 |
Michael Kramer | 167 | 1713 | 127224 |
Bruce L. Miller | 163 | 1153 | 115975 |
Peter A. R. Ade | 162 | 1387 | 138051 |
Marc W. Kirschner | 162 | 457 | 102145 |
Kaj Blennow | 160 | 1845 | 116237 |